Inovio(INO) price analysis shows huge potential
Inovio Pharmaceuticals Inc(INO) currently trades at $8.95 and has grown by 13% in the past 24 hours. Inovio develops immunotherapies and vaccines but hasn’t yet had a product approved for treatment. For INO-4800, preclinical testing was performed between Jan. 23 and Feb. 29. The company plans to begin clinical trials in the U.S. with 30 participants in April. It also plans to launch human trials in China and South Korea that same month, and says that it has a total of 3,000 doses prepared for the trials in the three countries.
Based on this information, investorsQ rates this stock a 7 out of 10. We give it this rating because Inovio said it expects to have the first results from the trial in the fall and to have 1 million does of the vaccine ready for additional clinical trials or emergency use by the end of the year. Inovio on March 12 announced a $5 million grant from the Bill & Melinda Gates Foundation to test a delivery device for its vaccine candidate. The high forecast for Inovio Pharmaceuticals Inc is $13 and the low is $7. Notably, the company’s market cap is $1.31 billion with a 52 week high of $19.36 and a 52 week low of $1.92.